(function(){var loadHandler=window['sl_{D0ADD9BC-5BCE-4B01-85F9-188A7AEC90E6}'];loadHandler&&loadHandler(184, '<div id="spr0_aefa55c"><div id="spr1_aefa55c" class="kern slide"><img id="img1_aefa55c" src="data/img2.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_aefa55c" class="kern slide"><div id="spr3_aefa55c" style="left:11.316px;top:59.274px;"><div id="spr4_aefa55c"><img id="img0_aefa55c" src="data/img267.png" width="698.116" height="476.961" alt=""/></div><div id="spr5_aefa55c" style="left:-0.003px;"><div style="width:0px;"><span id="txt0_aefa55c" data-width="318.216797" style="left:190.734px;top:-1.59px;">Routinely measured molecular biomarkers</span></div></div><div id="spr6_aefa55c" style="top:28.346px;"><div style="width:0px;"><span id="txt1_aefa55c" data-width="16.812500" style="left:5.4px;top:11.25px;">ER</span></div><div style="width:0px;"><span id="txt2_aefa55c" data-width="25.109375" style="left:5.4px;top:32.355px;">PgR</span></div></div><div id="spr7_aefa55c" style="left:286.281px;top:28.346px;"><div style="width:0px;"><span id="txt3_aefa55c" data-width="276.562500" style="left:5.4px;top:-0.44px;">Only ER+ve tumours respond to treatment</span></div><div style="width:0px;"><span id="txt4_aefa55c" data-width="255.546875" style="left:5.4px;top:21.64px;">ER-rich PgR+ve tumours respond belter</span></div><div style="width:0px;"><span id="txt5_aefa55c" data-width="309.343750" style="left:5.4px;top:42.745px;">However, ER-poor and PgR-ve still may respond</span></div></div><div id="spr8_aefa55c" style="top:94.586px;"><div style="width:0px;"><span id="txt6_aefa55c" data-width="35.015625" style="left:5.4px;top:21.315px;">HER2</span></div></div><div id="spr9_aefa55c" style="left:286.281px;top:94.586px;"><div style="width:0px;"><span id="txt7_aefa55c" data-width="295.671875" style="left:5.4px;top:-0.44px;">Co-expression of ER and HER2 is not common</span></div><div style="width:0px;"><span id="txt8_aefa55c" data-width="261.343750" style="left:5.4px;top:21.64px;">HER2+ve tumours have worse prognosis</span></div><div style="width:0px;"><span id="txt9_aefa55c" data-width="310.031250" style="left:5.4px;top:42.745px;">HER2+ve tumours require addition of Herceptin</span></div></div><div id="spr10_aefa55c" style="top:160.826px;"><div style="width:0px;"><span id="txt10_aefa55c" data-width="28.898438" style="left:5.4px;top:10.275px;">Ki67</span></div></div><div id="spr11_aefa55c" style="left:286.281px;top:160.826px;"><div style="width:0px;"><span id="txt11_aefa55c" data-width="217.390625" style="left:5.4px;top:-0.44px;">Measures proliferation in tumour</span></div><div style="width:0px;"><span id="txt12_aefa55c" data-width="364.570313" style="left:5.4px;top:20.665px;">High proliferation on treatment indicates poor response</span></div></div><div id="spr12_aefa55c" style="left:-0.003px;top:204.986px;"><div style="width:0px;"><span id="txt13_aefa55c" data-width="315.061523" style="left:192.919px;top:-1.59px;">Translational and experimental signatures</span></div></div><div id="spr13_aefa55c" style="top:233.333px;"><div style="width:0px;"><span id="txt14_aefa55c" data-width="23.289063" style="left:5.4px;top:13.845px;">SET</span></div><div style="width:0px;"><span id="txt15_aefa55c" class="relpos" data-width="49.576172" style="left:5.4px;top:35.308px;">Symmans </span><span id="txt16_aefa55c" class="relpos" data-width="25.386799" style="left:5.395px;top:35.308px;">et al</span><span id="txt17_aefa55c" class="relpos" data-width="128.039063" style="left:5.39px;top:35.308px;"> 2010 J Clin Oncol 28:4111</span></div></div><div id="spr14_aefa55c" style="left:286.281px;top:233.333px;"><div style="width:0px;"><span id="txt18_aefa55c" data-width="377.304688" style="left:5.4px;top:-0.44px;">Sensitivity to Endocrine Therapy (details on the next slide)</span></div><div style="width:0px;"><span id="txt19_aefa55c" data-width="288.867188" style="left:5.4px;top:21.64px;">Multi-gene expression signature (165 genes)</span></div><div style="width:0px;"><span id="txt20_aefa55c" data-width="273.804688" style="left:5.4px;top:42.745px;">Exploratory signature related to prognosis</span></div></div><div id="spr15_aefa55c" style="top:299.573px;"><div style="width:0px;"><span id="txt21_aefa55c" data-width="29.101563" style="left:5.4px;top:13.845px;">PEPI</span></div><div style="width:0px;"><span id="txt22_aefa55c" class="relpos" data-width="21.527344" style="left:5.4px;top:35.308px;">Ellis </span><span id="txt23_aefa55c" class="relpos" data-width="28.099689" style="left:5.395px;top:35.308px;">et al </span><span id="txt24_aefa55c" class="relpos" data-width="162.521484" style="left:5.39px;top:35.308px;">2008 J Natl Cancer Inst. 100:1380</span></div></div><div id="spr16_aefa55c" style="left:286.281px;top:299.573px;"><div style="width:0px;"><span id="txt25_aefa55c" data-width="264.812500" style="left:5.4px;top:-0.44px;">Preoperative Endocrine Prognostic Index</span></div><div style="width:0px;"><span id="txt26_aefa55c" data-width="330.492188" style="left:5.4px;top:21.64px;">Includes tumour size, lymph nodes, grede, ER, Ki67</span></div><div style="width:0px;"><span id="txt27_aefa55c" data-width="360.421875" style="left:5.4px;top:42.745px;">Extrapolates neo-adjuvant response to adjuvant setting</span></div></div><div id="spr17_aefa55c" style="top:365.813px;"><div style="width:0px;"><span id="txt28_aefa55c" data-width="80.664063" style="left:5.4px;top:2.805px;">Endopredict</span></div><div style="width:0px;"><span id="txt29_aefa55c" class="relpos" data-width="60.626953" style="left:5.4px;top:24.268px;">Kronenwett </span><span id="txt30_aefa55c" class="relpos" data-width="28.099689" style="left:5.395px;top:24.268px;">et al </span><span id="txt31_aefa55c" class="relpos" data-width="122.953125" style="left:5.39px;top:24.268px;">2012 BMC Cancer 12:456</span></div></div><div id="spr18_aefa55c" style="left:286.281px;top:365.813px;"><div style="width:0px;"><span id="txt32_aefa55c" data-width="280.757813" style="left:5.4px;top:-0.44px;">Multi-gene expression signature (11 genes)</span></div><div style="width:0px;"><span id="txt33_aefa55c" data-width="352.078125" style="left:5.4px;top:20.665px;">Estimates prognosis for adjuvant endocrine treatment</span></div></div><div id="spr19_aefa55c" style="top:409.973px;"><div style="width:0px;"><span id="txt34_aefa55c" data-width="255.640625" style="left:5.4px;top:5.565px;">Signatures from Edinburgh Breast Unit</span></div><div style="width:0px;"><span id="txt35_aefa55c" class="relpos" data-width="31.388672" style="left:5.4px;top:27.755px;">Miller </span><span id="txt36_aefa55c" class="relpos" data-width="28.099689" style="left:5.395px;top:27.755px;">et al </span><span id="txt37_aefa55c" class="relpos" data-width="125.326172" style="left:5.39px;top:27.755px;">2009 J Clin Oncol 27:1382</span></div><div style="width:0px;"><span id="txt38_aefa55c" class="relpos" data-width="43.470703" style="left:5.4px;top:43.588px;">Turnbull </span><span id="txt39_aefa55c" class="relpos" data-width="28.099689" style="left:5.395px;top:43.588px;">et al </span><span id="txt40_aefa55c" class="relpos" data-width="125.326172" style="left:5.39px;top:43.588px;">2015 J Clin Oncol 33:2270</span></div></div><div id="spr20_aefa55c" style="left:286.281px;top:409.973px;"><div style="width:0px;"><span id="txt41_aefa55c" data-width="334.945313" style="left:5.4px;top:-0.44px;">Multi-gene expression signatures (4 and 205 genes)</span></div><div style="width:0px;"><span id="txt42_aefa55c" data-width="337.460938" style="left:5.4px;top:21.64px;">Look at pre-treatment and on 2-weeks of treatment</span></div><div style="width:0px;"><span id="txt43_aefa55c" data-width="299.226563" style="left:5.4px;top:42.745px;">Predict neo-adjuvant response after 3 months</span></div></div></div><div id="spr21_aefa55c" style="top:10.706px;"><div style="width:0px;"><span id="txt44_aefa55c" data-width="441.656250" style="left:26.591px;top:0.564px;">Selected biomarkers for endocrine treatment</span></div></div></div></div>');})();